Floatz logo

Autologous Anti-Cd19Car-4-1Bb-Cd3Zeta-Egfrt-Expressing Cd4+/Cd8+ Central Memory T-Lymphocytes Jcar014

Diffuse Large B-Cell Lymphoma, Not Otherwise Specified

Fred Hutchinson Cancer CenterCell therapyPhase 1Dormant
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
89/ 100

Competitive context

271 Active assets in the Diffuse Large B-Cell Lymphoma, Not Otherwise Specified cohort.

Asset / SponsorPhaseRating
VINCRISTINE SULFATE
National Cancer Institute (NCI)
Phase 2/3A
Evomela
Ruijin Hospital
Phase 4BBB
Axicabtagene Ciloleucel
Ruijin Hospital
Phase 4BBB
PREDNISONE TABLETS
Beth Israel Deaconess Medical Center
Phase 4BBB
Inno-206
Beth Israel Deaconess Medical Center
Phase 4BBB

View all 50 →

Same molecule, other indications

Autologous Anti-Cd19Car-4-1Bb-Cd3Zeta-Egfrt-Expressing Cd4+/Cd8+ Central Memory T-Lymphocytes Jcar014 is also rated in:

primary mediastinal large B-cell lymphomaDormant
CC
Indicative ·
43 / 100
View asset →
Refractory High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 RearrangementsDormant
CC
Indicative ·
41 / 100
View asset →
relapsed/refractory diffuse large B-cell lymphomaDormant
C
Indicative ·
39 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →